GlassScriptPhysician profile
Leonard D Weiner
NPI 1952571085
$3,555.05
in general payments reported to CMS, 2019-2025
24 companies · $1,468 in 2025
The $1,468 reported for 2025 was more than what 86% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $330 · 2022: $416 · 2023: $415 · 2024: $927 · 2025: $1,468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,790 · Education: $19.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,790.16 |
| Education | $19.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $783.18 | 2021-2025 | Farxiga, Lokelma |
| Novo Nordisk INC | $279.54 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Calliditas Therapeutics US INC. | $279.34 | 2023-2025 | Tarpeyo |
| Amgen INC. | $253.40 | 2022-2025 | Tavneos, Aranesp, Parsabiv |
| Otsuka America Pharmaceutical, INC. | $226.32 | 2021-2025 | Jynarque, Voyxact |
| Ardelyx, INC. | $164.74 | 2023-2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $158.92 | 2021-2025 | |
| Travere Therapeutics, INC. | $148.67 | 2023-2025 | Filspari |
| Bard Peripheral Vascular, INC. | $146.22 | 2021 | |
| Vifor Pharma, INC. | $125.24 | 2022-2025 | Veltassa, Korsuva |
| Fresenius USA Marketing, INC. | $124.55 | 2022-2024 | Velphoro |
| Aurinia Pharma U.S., INC. | $123.34 | 2022-2025 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.19 | 2024-2025 | Jardiance |
| Verrica Pharmaceuticals INC. | $98.41 | 2024 | Ycanth |
| Opko Pharmaceuticals, LLC | $89.72 | 2022-2025 | Rayaldee |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $81.78 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $66.14 | 2023-2025 | |
| Daiichi Sankyo INC. | $61.65 | 2022-2024 | Injectafer |
| Apellis Pharmaceuticals, INC. | $59.44 | 2025 | Empaveli |
| Lilly USA, LLC | $50.65 | 2025 | Jardiance |
| Mallinckrodt Hospital Products INC. | $44.06 | 2022-2025 | Acthar, Terlivaz |
| Akebia Therapeutics INC | $30.22 | 2022-2024 | Auryxia |
| Glaxosmithkline, LLC. | $27.98 | 2022-2024 | Benlysta, Jesduvroq |
| Renalytix Ai, INC. | $14.35 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonard Weiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.